Phase 4 N=26 A Clinical Study to Assess the Efficacy and Safety of a Healing Ointment on Diaper Rash
Diaper Rash
Primary: Skin Texture — 1.8; 0.5; 0 Score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=149 The Use of Coconut Oil for the Prevention and Treatment of Diaper Dermatitis in the NICU Population
Dermatitis, Contact
Primary: The Number of Days Free From Diaper Dermatitis — 4.065; 4.274 Days
Phase 4 N=200 Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
Diaper Rash
Primary: Number of Participants With Overall Cure (OC) — 49; 119 participants
N/A N=167 Prevention of Incontinence-associated Dermatitis
Incontinence-associated Dermatitis
Primary: Incidence of Incontinence-associated Dermatitis (IAD) — 18; 8; 5; 5 Participants
Phase 3 N=51 A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin
Eczema
Primary: Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline — -1.783; -0.767 units on a scale — p=<0.0001
N/A N=1,260 A Community-based Assessment of Skin Care, Allergies, and Eczema
Atopic Dermatitis · Atopic Disorders · Eczema
Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019
Phase 4 N=42 Promiseb Topical Cream for Cradle Cap
Cradle Cap · Infantile Seborrheic Dermatitis
Primary: Subjects With Investigator Global Assessment (IGA) Success (IGA of 0 or 1) at End of Treatment (Day 7 or 14). — 91.7; 96 percentage of participants — p=>0.05
N/A N=16 A Clinical Evaluation of 3M Cavilon Advanced Barrier Film for the Treatment of Incontinence Associated Dermatitis (IAD)
Dermatitis
Primary: Number of Participants With Change in Incontinence Associated Dermatitis Score — 13; 1; 2 participants
N/A N=41 Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
Atopic Dermatitis (AD)
Primary: Percentage With Erythema on the Face at Baseline Before Investigational Product Application — 33.3; 71.9; 55.6; 6.3 Percentage of participants
N/A N=100 Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants
Atopic Dermatitis
Primary: Percentage of Participants With Cumulative Atopic Dermatitis Diagnosed by Investigator at 12 Months — 13.2; 25 Percentage of participants
Phase 4 N=100 Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in Three Item Severity Score — -2.6; -3.6 units on a scale
Phase 3 N=112 Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media
Acute Otitis Media
Primary: The Distribution of Participants Receiving Formulation 1 for Whom Protocol-Defined Diarrhea (PDD) Was Reported and Associated With Study Product — 10; 30 Participants
N/A N=31 A Tolerability Assessment Study of Three Wash Products in Infants
Skin Care
Primary: Tolerability Assessment of Test Products — 9; 10; 11; 1 Participants
N/A N=48 Very Low Birth Weight Preterm Infant Bundled Care in the NICU
Preterm Infants
Primary: Mean Heart Rate by Group — 200; 185 beats per minute
Phase 1 N=46 A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% Ointment
Healthy
Primary: Skin Irritation Score — 0; 0; 339; 15 Normalized cumulative irritation score — p=<0.0001
Phase 2 N=22 An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis
Atopic Dermatitis
Primary: Incidence of Skin Irritation — 0 Participants
Phase 2 N=20 Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy
Breast Cancer · Skin Reactions Secondary to Radiation Therapy
Primary: Percent of Women Who Develop Grade 3 or 4 Radiation Dermatitis (as Defined by the Stanford Radiation Dermatitis Scoring System) During a Course of Radiation Therapy — 6…
Phase 3 N=124 Controlled Study to Evaluate the Efficacy and Safety of Racecadotril in Infants, Children and Adolescents With Acute Diarrhea
Diarrhea
Primary: Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5…
N/A N=71 Oral Zinc for the Treatment of Acute Diarrhea in US Children
Diarrhea · Gastroenteritis
Primary: Duration of Diarrhea in Acute Diarrheal Illnesses in a Developed Nation While Taking Zinc or Placebo. — 73; 72; 48; 76.8 Hours — p=0.88
Phase 4 N=39 Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis
Atopic Dermatitis
Primary: Investigator Global Assessment of Improvement — 2; 2; 2 units on a scale
N/A N=50 Clinical Investigation on the Efficacy and Safety of Relizema Cream in Paedriatric Patients
Atopic Dermatitis
Primary: To Evaluate and Confirm the Performance of the Relizema Cream in the Improvement of the Dermatitis Severity in Paediatric Patients. — 17; 13 Participants
Phase 3 N=11 Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have · Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Primary: Number of Patients in Which the PI Observed a Notable Difference in the Number of Lesions — 4; 4 participants
Phase 3 N=31 Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea
Diarrhea, Infantile
Primary: Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5…
Phase 3 N=143 Micronutrient Sprinkles in a Daycare Center
Diarrhea · Respiratory Infection
Primary: Proportion of Children of Diarrhea Episodes — 19.1; 14.7 percentage of participants
Phase 2 N=53 Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema
Atopic Dermatitis
Primary: Change From Baseline in the Itch Assessment Score Immediately Following Treatment — 1.93; 2.64 units on a scale — p=<0.001
Phase 4 N=137 A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Site Reactions — 88; 1; 15 Participants
N/A N=106 Using Dexpanthenol Cream to Prevent Lip Corner Cracks in Children After Tonsil/Adenoid Surgery
Cheilitis, Angular · Postoperative Complications · Adenotonsillar Hypertrophy
Primary: Incidence of Angular Cheilitis — 5; 22; 46; 28 Participants
N/A N=90 Human Testing of an Over-the-Counter (OTC) Cream in Children With Eczema
Atopic Dermatitis
Primary: Eczema Area and Severity Index (EASI) — 3.014; 3.359; 1.286; 1.621 units on a scale
Phase 4 N=528 CeraVe Diabetes Mellitus
Diabetes Complications
Primary: Percentage of Participants Reporting Adverse Events (AE) — 0 percentage of participants
N/A N=120 Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis
Atopic Dermatitis
Primary: Time to Relapse (Quantile 25%) — 48; 15 Days